Abstract
To explore the association of serum tumor abnormal protein (TAP) with other serological biomarkers e.g. carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125), carbohydrate antigen 19-9 (CA19-9) and its clinical application in colorectal cancer (CRC) patients. Patients (N=98) were enrolled into this study with histologically or cytologically confirmed CRC. Using a test kit, the level of TAP was determined, while chemiluminescence was used to measure the levels of some other common serological biomarkers e.g. CEA, CA125 and CA19-9. The area of TAP condensed particulate matter decreased after chemotherapy compared with before chemotherapy when CT or MRI scans showed disease control. In contrast, it increased with disease progression (P<0.05). Furthermore, a statistically significant difference was confirmed in monitoring of TAP and common serological biomarkers e.g. CEA and CA19-9 (p<0.05). Detecting TAP in CRC patients has high sensitivity and specificity and can be used as a new independent indicator for clinically monitoring CRC patients in the course of chemotherapy.
Highlights
Colorectal cancer (CRC) is one of the commonest cancers in both men and women with an estimated annual incidence of 1 million new cases (Ferlay et al, 2010), and the third most commonly diagnosed cancer and the third leading cause of cancer death world-wide (Jemal et al, 2011)
The area of tumor abnormal protein (TAP) condensed particulate matter decreased after chemotherapy compared with before chemotherapy when CT or MRI scans showed disease control
The area of TAP condensed particulate matter decreased after chemotherapy compared with before chemotherapy when CT or MRI scan showed disease controlled, in contrary, it increased when disease progressed (P
Summary
Colorectal cancer (CRC) is one of the commonest cancers in both men and women with an estimated annual incidence of 1 million new cases (Ferlay et al, 2010), and the third most commonly diagnosed cancer and the third leading cause of cancer death world-wide (Jemal et al, 2011). The prognosis in CRC patients is dependent on the stage at which the disease is diagnosed. Due to a frequent lack of early diseasespecific symptoms and a reluctance to seek medical investigation, many CRC cases present late when the disease is at a relatively advanced stage. A meta-analysis of trials based on screening with fecal occult blood (FOB) tests indicated a 25% reduction in CRC-related mortality (Hewitson et al, 2008). Recent results of flexible sigmoidoscopy-based screening programs have shown dramatic reductions in CRC incidence and mortality (Elmunzer et al, 2012). Detection of CRC in its localized or preinvasive form is likely to represent the most realistic approach to reducing the number of cancer-related deaths (Brenner et al, 2014). An alternative strategy is to develop reliable and specific biomarkers detectable in a more readily accessible medium, such as the peripheral blood, that can accurately and reliably detect CRC in its earliest stages when treatment options can be maximized (Brenner et al, 2013)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
